Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $490,160.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $61.27, for a total value of $490,160.00. Following the completion of the sale, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at $5,862,252.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, March 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $69.02, for a total value of $552,160.00.

Vaxcyte Trading Up 1.3 %

PCVX traded up $0.77 on Monday, reaching $61.60. The stock had a trading volume of 627,167 shares, compared to its average volume of 836,746. The company has a market capitalization of $6.70 billion, a price-to-earnings ratio of -15.04 and a beta of 0.89. Vaxcyte, Inc. has a fifty-two week low of $41.57 and a fifty-two week high of $82.04. The firm has a 50-day moving average of $69.39 and a 200-day moving average of $61.12.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same period in the prior year, the company posted ($0.73) earnings per share. Sell-side analysts anticipate that Vaxcyte, Inc. will post -4.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in PCVX. Parallel Advisors LLC lifted its holdings in shares of Vaxcyte by 155.3% during the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. Banque Cantonale Vaudoise lifted its holdings in Vaxcyte by 96.7% during the 1st quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock worth $81,000 after buying an additional 582 shares during the period. Avior Wealth Management LLC bought a new stake in shares of Vaxcyte in the 3rd quarter valued at about $178,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Vaxcyte in the fourth quarter valued at about $208,000. Finally, Rathbones Group PLC acquired a new stake in shares of Vaxcyte in the third quarter valued at about $221,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Bank of America increased their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Needham & Company LLC restated a “buy” rating and set a $95.00 price objective on shares of Vaxcyte in a research report on Wednesday, April 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte currently has a consensus rating of “Buy” and an average price target of $78.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.